<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Annals of Clinical Microbiology and Antimicrobials - Most viewed articles</title>
		<link>http://www.ann-clinmicrob.commostviewed/</link>
		<description>Most viewed articles in last 30 days from Annals of Clinical Microbiology and Antimicrobials (ISSN 1476-0711) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
         <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/7/1/13"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/6/1/16"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/7/1/14"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/7/1/7"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/7/1/12"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/7/1/15"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/7/1/11"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/3/1/13"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/7/1/5"/>			    
            
				    <rdf:li rdf:resource="http://www.ann-clinmicrob.com/content/6/1/4"/>			    
            
            </rdf:Seq>
        </items>
    </channel>
    
		<item rdf:about="http://www.ann-clinmicrob.com/content/7/1/13">
            
            <title>Antimicrobial resistance in community and nosocomial Escherichia coli urinary tract isolates, London 2005 &#8211; 2006</title>
			<description>Background:
Escherichia coli is the commonest cause of community and nosocomial urinary tract infection (UTI). Antibiotic treatment is usually empirical relying on susceptibility data from local surveillance studies. We therefore set out to determine levels of resistance to 8 commonly used antimicrobial agents amongst all urinary isolates obtained over a 12 month period.
Methods:
Antimicrobial susceptibility to ampicillin, amoxicillin/clavulanate, cefalexin, ciprofloxacin, gentamicin, nitrofurantoin, trimethoprim and cefpodoxime was determined for 11,865 E. coli urinary isolates obtained from community and hospitalised patients in East London.
Results:
Nitrofurantoin was the most active agent (94% susceptible), followed by gentamicin and cefpodoxime. High rates of resistance to ampicillin (55%) and trimethoprim (40%), often in combination were observed in both sets of isolates. Although isolates exhibiting resistance to multiple drug classes were rare, resistance to cefpodoxime, indicative of Extended spectrum &#946;-lactamase production, was observed in 5.7% of community and 21.6% of nosocomial isolates.
Conclusion:
With the exception of nitrofurantoin, resistance to agents commonly used as empirical oral treatments for UTI was extremely high. Levels of resistance to trimethoprim and ampicillin render them unsuitable for empirical use. Continued surveillance and investigation of other oral agents for treatment of UTI in the community is required.</description>
			<link>http://www.ann-clinmicrob.com/content/7/1/13</link>		
			<dc:creator>David C Bean, Daniel Krahe and David W Wareham</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2008, 7:13</dc:source>
			<dc:subject>Number of accesses: 764</dc:subject>
			<dc:date>2008-06-18</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-7-13</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-18</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/6/1/16">
            
            <title>Infections caused by mycobacterium tuberculosis in patients with hematological disorders and in recipients of hematopoietic stem cell transplant, a twelve year retrospective study</title>
			<description>Background:
Tuberculous infections in patients with hematological disorders and hematopoietic stem cell transplant vary in incidence, complications and response to treatment.Methods and materialsA retrospective study of patients with various benign and malignant hematological disorders and recipients of hematopoietic stem cell transplant who were treated at Riyadh Armed Forces Hospital, Saudi Arabia between January 1991 and December 2002 and who developed tuberculous infections was conducted.
Results:
Tuberculous infections occurred in eighteen patients with hematological disorders and hematopoietic stem cell transplant. The main associated factors were: reduced immunity due to the primary hematological disorder, age more than 50 years and the administration of cytotoxic chemotherapy, steroids or radiotherapy. These infections frequently involved the lungs and predominantly occurred in males and in patients with chronic myeloproliferative disorders, myelodysplastic syndrome and acute myeloid leukemia. In patients treated with intravenous cytotoxic chemotherapy, tuberculous infections tended to occur earlier and also tended to be more disseminated compared to infections occurring in patients treated with oral chemotherapy. Anti-tuberculous treatment was given to 16 patients and it was successful in 15 of these patients.
Conclusion:
Tuberculous infections cause significant morbidity and mortality in patients with various hematological disorders and in recipients of hematopoietic stem cell transplant. The early administration of anti-tuberculous therapy and compliance with drug treatment are associated with successful outcomes while delayed management, drug resistance and the presence of miliary infections are associated with poor prognosis and high mortality rates.</description>
			<link>http://www.ann-clinmicrob.com/content/6/1/16</link>		
			<dc:creator>Khalid Ahmed Al-Anazi, Asma Marzouq Al-Jasser and David Alan Price Evans</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2007, 6:16</dc:source>
			<dc:subject>Number of accesses: 540</dc:subject>
			<dc:date>2007-11-16</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-6-16</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-11-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/7/1/14">
            
            <title>Changes in the predominant human Lactobacillus flora during in vitro fertilisation</title>
			<description>Background:
Signature matching of nucleotide sequences in the V1 and V3 regions 16S rRNA genes using pyrosequencing technology is a powerful tool for typing vaginal Lactobacilli to the species level and has been used for investigating the vaginal microbial niche.
Methods:
This study has characterized the normal cultivable vaginal Lactobacillus flora at varying estradiol levels in plasma; the study comprised 17 patients undergoing ovarian stimulation for In Vitro Fertilization (IVF) treatment. The vaginal status of each participant was initially assessed as normal according to Amsel and Nugent criteria.
Results:
L. crispatus, L. gasseri and/or L. jensenii were present in 10 of the patients throughout the study period, and little variation among these three species was encountered in individual patients. The flora of three women was dominated by L. delbr&#252;eckii, L. rhamnosus or L. vaginalis. One woman exhibited a dominance of L. iners. The flora of the remaining three women were initially dominated by L. rhamnosus or L. reuteri, but as their estrogen levels rose, their flora composition altered, to become dominated by one of the three species most common in a normal, healthy vagina.
Conclusion:
Signature matching of nucleotide sequences in the V1 and V3 regions of 16S rRNA genes is a discriminative tool for the study of vaginal Lactobacilli and can be used to track the Lactobacillus flora under a variety of physiological conditions.</description>
			<link>http://www.ann-clinmicrob.com/content/7/1/14</link>		
			<dc:creator>Tell Jakobsson and Urban Forsum</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2008, 7:14</dc:source>
			<dc:subject>Number of accesses: 469</dc:subject>
			<dc:date>2008-06-30</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-7-14</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/7/1/7">
            
            <title>Primary psoas abscess due to Streptococcus milleri</title>
			<description>Primary Psoas abscess (PPA) is an infrequent clinical entity with obscure pathogenesis and vague clinical presentation. High index of clinical suspicion is required for the diagnosis of psoas abscess. We also emphasises the importance of bacteriological confirmation of microorganism involved, although Staphylococcus aureus remains the commonest pathogen. We report an extremely rare case of PPA caused by Streptococcus milleri. Only one case has been reported in literature so far.</description>
			<link>http://www.ann-clinmicrob.com/content/7/1/7</link>		
			<dc:creator>Nitin B Bagul, Abeywardana MS Abeysekara and Sabu Jacob</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2008, 7:7</dc:source>
			<dc:subject>Number of accesses: 365</dc:subject>
			<dc:date>2008-02-26</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-7-7</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>7</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/7/1/12">
            
            <title>Imported PER-1 producing Pseudomonas aeruginosa, PER-1 producing Acinetobacter baumanii and VIM-2-producing Pseudomonas aeruginosa strains in Hungary</title>
			<description>IntroductionPseudomonas aeruginosa and Acinetobacter baumanii are important nosocomial pathogens with wide intrinsic resistance. However, due to the dissemination of the acquired resistance mechanisms, such as extended-spectrum beta-lactamase (ESBL) and metallo beta-lactamase (MBL) production, multidrug resistant strains have been isolated more often.Case presentationWe report a case of a Hungarian tourist, who was initially hospitalized in Egypt and later transferred to Hungary. On the day of admission PER-1-producing P. aeruginosa, PER-1 producing A. baumannii, SHV-5-producing Klebsiella pneumoniae and VIM-2-producing P. aeruginosa isolates were subcultured from the patient's samples in Hungary. Comparing the pulsed-field gel electrophoresis (PFGE) patterns of the P. aeruginosa strains from the patient to the P. aeruginosa strains occurring in this hospital, we can state that the PER-1-producing P. aeruginosa and VIM-2-producing P. aeruginosa had external origin.
Conclusion:
This is the first report of PER-1-producing P. aeruginosa,and PER-1-producing A. baumanii strains in Hungary. This case highlights the importance of spreading of the beta-lactamase-mediated resistance mechanisms between countries and continents, showing the importance of careful screening and the isolation of patients arriving from a different country.</description>
			<link>http://www.ann-clinmicrob.com/content/7/1/12</link>		
			<dc:creator>Dora Szab&#243;, Julia Szentandr&#225;ssy, Zsuzsa Juh&#225;sz, Katalin Katona, K&#225;roly Nagy and L&#225;szl&#243; R&#243;kusz</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2008, 7:12</dc:source>
			<dc:subject>Number of accesses: 318</dc:subject>
			<dc:date>2008-05-30</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-7-12</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>12</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/7/1/15">
            
            <title>In- vitro antimycobacterial drug susceptibility testing of Non-Tubercular Mycobacteria by Tetrazolium Microplate Assay </title>
			<description>Background:
Non-tubercular mycobacteria (NTM) has not been given due attention till the recent epidemic of HIV. This has led to increasing interest of health care workers in their biology, epidemiology and drug resistance. However, timely detection and drug susceptibility profiling of NTM isolates are always difficult in resource poor settings like India. Furthermore, no standardized methodology or guidelines are available to reproduce the results with clinical concordance.ObjectiveTo find an alternative and rapid method for performing the drug susceptibility assay in a resource limited settings like India, we intended to evaluate the utility of Tetrazolium microplate assay (TEMA) in comparison with proportion method for reporting the drug resistance in clinical isolates of NTM. 
Methods:
A total of fifty-five NTM isolates were tested for susceptibility against Streptomycin, Rifampicin, Ethambutol, Ciprofloxacin, Ofloxacin, Azithromycin, and Clarithromycin by TEMA and the results were compared with agar proportion method (APM).  
Results:
Of the 55 isolates, 23 (41.8%) were sensitive to all the drugs and the remaining 32 (58.2%) were resistant to at least one drug. TEMA had very good concordance with APM except with minor discrepancies. Susceptibility results were obtained in the median of 5 to 9 days by TEMA. The NTM isolates were highly sensitive against Ofloxacin (98.18% sensitive) and Ciprofloxacin (90.09% sensitive). M. mucogenicum was sensitive only to Clarithromycin and resistant to all the other drugs tested. The concordance between TEMA and APM ranged between 96.4 - 100%.
Conclusion:
Tetrazolium Microplate Assay is a rapid and highly reproducible method. However, it must be performed only in tertiary level Mycobacteriology laboratories with proper bio-safety conditions. </description>
			<link>http://www.ann-clinmicrob.com/content/7/1/15</link>		
			<dc:creator>Manimuthu Mani Sankar, Krishnamoorthy Gopinath, Rupak Singla and Sarman Singh</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2008, 7:15</dc:source>
			<dc:subject>Number of accesses: 294</dc:subject>
			<dc:date>2008-07-11</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-7-15</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-07-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/7/1/11">
            
            <title>An uncommon presentation for a severe invasive infection due to methicillin-resistant Staphylococcus aureus clone USA300 in Italy: a case report</title>
			<description>Background:
Methicillin resistant Staphylococcus aureus (MRSA) has been considered for many years a typical nosocomial pathogen. Recently MRSA has emerged as a frequent cause of infections in the community. More commonly, community-acquired (CA)-MRSA is a cause of infections of the skin and soft-tissues, but life-threatening infections such as necrotizing pneumonia and sepsis can occasionally occur.Case presentationThis report describes an uncommon presentation of invasive CA-MRSA infection in an adolescent without known risk factors. The presentation was typical for bacterial meningitis, but the clinical findings also revealed necrotizing pneumonia. Following the development of deep venous thrombosis, the presence of an inherited trombophilic defect (factor V Leiden) was detected. The patient was successfully treated with an antibiotic combination including linezolid and with anticoagulant therapy. CA-MRSA was isolated from both cerebrospinal fluid and blood. The isolates were resistant to oxacillin and other beta-lactam antibiotics and susceptible to the other antibiotics tested including erythromycin. Molecular typing revealed that the strains contained the Panton-Valentine leukocidin genes and type IV SCCmec, and were ST8, spa type t008, and agr type 1. This genetic background is identical to that of the USA300 clone.
Conclusion:
This report highlights that meningitis can be a new serious presentation of CA-MRSA infection. CA-MRSA strains with the genetic background of the USA300 clone are circulating in Italy and are able to cause severe infections.</description>
			<link>http://www.ann-clinmicrob.com/content/7/1/11</link>		
			<dc:creator>Piero Valentini, Gabriella Parisi, Monica Monaco, Francesca Crea, Teresa Spanu, Orazio Ranno, Mirella Tronci and Annalisa Pantosti</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2008, 7:11</dc:source>
			<dc:subject>Number of accesses: 272</dc:subject>
			<dc:date>2008-04-30</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-7-11</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>11</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/3/1/13">
            
            <title>Kirby-Bauer disc approximation to detect inducible third-generation cephalosporin resistance in Enterobacteriaceae</title>
			<description>Resistance to &#946;-lactam antibiotics in enteric Gram-negative bacilli may be difficult to detect using standard methods of either Kirby-Bauer disc diffusion (KBDD) or broth dilution for minimal inhibitory concentration (MIC). This difficulty is due to genetic differences in resistance determinants, differences in levels of gene expression, and variation in spectra of enzymatic activity against the substrate &#946;-lactams used for susceptibility testing. We have examined 95 clinical isolates reportedly susceptible to ceftazidime and ceftriaxone, as originally determined by either KBDD or MIC methods. The organisms studied here were isolated in 2002 from two pediatric hospital centers (Seattle, USA and Shanghai, China). They belong to the inducible &#946;-lactamase producing Gram-negative bacilli, such as Enterobacter spp., Citrobacter spp., Serratia spp., Morganella spp., Providencia spp., and Proteus vulgaris. A Kirby-Bauer disc approximation (KBDA) method identified inducible phenotypes of third-generation cephalosporin resistance in 76% of isolates, which would otherwise be considered susceptible by standard KBDD methods.</description>
			<link>http://www.ann-clinmicrob.com/content/3/1/13</link>		
			<dc:creator>Xuan Qin, Scott J Weissman, Mary Frances Chesnut, Bei Zhang and Lisong Shen</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2004, 3:13</dc:source>
			<dc:subject>Number of accesses: 250</dc:subject>
			<dc:date>2004-07-15</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-3-13</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>3</prism:volume>
					
			
							
					<prism:startingPage>13</prism:startingPage>
					
			
							
					<prism:publicationDate>2004-07-15</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/7/1/5">
            
            <title>Fatal necrotizing pneumonia due to a Panton-Valentine leukocidin positive community-associated methicillin-sensitive Staphylococcus aureus and Influenza co-infection: a case report</title>
			<description>Recent studies have described a number of fatalities due to methicillin-resistant Staphylococcus aureus (MRSA) and influenza virus co-infection. MRSA isolates provide a challenge to caregivers due to inherent wide range antibiotic resistance. Many facilities have instituted screening methods, based on the presence of antibiotic resistance genes, to identify MRSA positive patients upon admission. However, the resistance profile of the pathogen does not necessarily determine the severity of disease caused by that organism.We describe a fatal case of necrotizing pneumonia in a patient co-infected with Influenza B and a community-associated, PVL-positive methicillin-susceptible Staphylococcus aureus (MSSA).</description>
			<link>http://www.ann-clinmicrob.com/content/7/1/5</link>		
			<dc:creator>Jill C Roberts, Sam P Gulino, K Kealy Peak, Vicki A Luna and Roger Sanderson</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2008, 7:5</dc:source>
			<dc:subject>Number of accesses: 243</dc:subject>
			<dc:date>2008-02-19</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-7-5</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>5</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-02-19</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.ann-clinmicrob.com/content/6/1/4">
            
            <title>Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India</title>
			<description>Background:
Urinary tract infections (UTIs) remain the common infections diagnosed in outpatients as well as hospitalized patients. Current knowledge on antimicrobial susceptibility pattern is essential for appropriate therapy. Extended-Spectrum beta-Lactamase (ESBL) producing bacteria may not be detected by routine disk diffusion susceptibility test, leading to inappropriate use of antibiotics and treatment failure. The aim of this study was to determine the distribution and antibiotic susceptibility patterns of bacterial strains isolated from patients with community acquired urinary tract infections (UTIs) at Aligarh hospital in India as well as identification of ESBL producers in the population of different uropathogens.
Methods:
Urinary isolates from symptomatic UTI cases attending to the JN Medical College and hospital at Aligarh were identified by conventional methods. Antimicrobial susceptibility testing was performed by Kirby Bauer's disc diffusion method. Isolates resistant to third generation cephalosporin were tested for ESBL production by double disk synergy test method.
Results:
Of the 920 tested sample 100 samples showed growth of pathogens among which the most prevalent were E. coli (61%) followed by Klebsiella spp (22%). The majority (66.66%) of the isolates were from female while the remaining were from male. Among the gram-negative enteric bacilli high prevalence of resistance was observed against ampicillin and co-trimoxazole. Most of the isolates were resistant to 4 or more number of antibiotics. Forty two percent of isolates were detected to produce ESBL among which 34.42 % were E. coli isolates.
Conclusion:
This study revealed that E. coli was the predominant bacterial pathogen of community acquired UTIs in Aligarh, India. It also demonstrated an increasing resistance to Co-trimoxazole and production of extended spectrum &#946;-lactamase among UTI pathogens in the community. This study is useful for clinician in order to improve the empiric treatment.</description>
			<link>http://www.ann-clinmicrob.com/content/6/1/4</link>		
			<dc:creator>Mohammed Akram, Mohammed Shahid and Asad U Khan</dc:creator>
			<dc:source>Annals of Clinical Microbiology and Antimicrobials 2007, 6:4</dc:source>
			<dc:subject>Number of accesses: 226</dc:subject>
			<dc:date>2007-03-23</dc:date>
			<dc:identifier>doi:10.1186/1476-0711-6-4</dc:identifier>
			
			
							
					<prism:publicationName>Annals of Clinical Microbiology and Antimicrobials</prism:publicationName>
					
			
							
					<prism:issn>1476-0711</prism:issn>
					
			
							
					<prism:volume>6</prism:volume>
					
			
							
					<prism:startingPage>4</prism:startingPage>
					
			
							
					<prism:publicationDate>2007-03-23</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
	<cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
